Compare MTB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTB | INSM |
|---|---|---|
| Founded | 1856 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3B | 35.2B |
| IPO Year | N/A | 2000 |
| Metric | MTB | INSM |
|---|---|---|
| Price | $224.94 | $149.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 23 |
| Target Price | ★ $222.55 | $188.73 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.95 | $130.70 |
| Revenue Next Year | $3.75 | $74.05 |
| P/E Ratio | $13.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $150.75 | $60.40 |
| 52 Week High | $239.00 | $212.75 |
| Indicator | MTB | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 39.89 |
| Support Level | $178.77 | $139.81 |
| Resistance Level | $239.00 | $149.08 |
| Average True Range (ATR) | 5.42 | 6.89 |
| MACD | -1.88 | 0.82 |
| Stochastic Oscillator | 38.13 | 21.35 |
M&T Bank is a US regional bank with roughly $210 billion in assets as of June 30, 2025. Headquartered in Buffalo, New York, the bank's footprint is mostly concentrated in New England and the US Mid-Atlantic. M&T Bank boasts a community banking approach, and boasts over 900 branches in 13 states and Washington, D.C. Apart from retail and commercial banking, M&T Bank also has wealth management operations through Wilmington Trust and a partnership with LPL Financial, and a corporate trust businesses.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.